Genentech privatization On March 26, 2009, Genentech, Inc. became a wholly-owned member of the Roche Group. In connection with the privatization, public shareholders received $95.00 per share for their shares and Genentech's common stock (symbol: DNA) ceased trading on the New York Stock Exchange.
Share tendering
Questions regarding Genentech shares not tendered in the privatization transaction should be directed to BNY Mellon Shareowner Services by phone:
+1 866-223-9154 from within the United States, Canada or Puerto Rico (toll free)
+1 201-680-6579 from outside the United States
Phones are open 9am to 6pm New York time, Monday through Friday, except for bank holidays.
Transmittal materials By Mail:
BNY Mellon Shareowner Services
Attn: Corporate Action Dept.
PO Box 358300
Pittsburgh, PA 15252-8300
By Overnight Courier or By Hand:
BNY Mellon Shareowner Services
Attn: Corporate Action Dept., 27th Floor
480 Washington Boulevard
Jersey City, NJ 07310
More information
Roche Investor Relations North America
Information for U.S. Investors